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INTRODUCTION 
Chronic respiratory diseases affects the airways and other structures of 
lungs.This group consist of diseases like COPD, emphysema, bronchitis, 
asthma, chronic pleural diseases, pneumoconiosis, pulmonary eosinophilia, 
sarcoidosis, sleep apnea syndrome and pulmonary heart diseases. Other 
conditions like cystic fibrosis, pulmonary fibrosis and occupational lung 
diseases are included in this group.2  
Usual presentations of these diseases were, cough, pain in throat or chest, 
abnormalities of breathing, bleeding of respiratory passages. Signs involving 
respiratory and circulatory system were asphyxia, pleurisy, productive sputum 
and cardio respiratory arrest.1  
Chronic respiratory diseases contribute four million deaths per year 
worldwide, contributing to 5% of deaths anually.1 By Disability Adjusted Life 
years of 2005 data, chronic respiratory diseases contributed 4% death 
worldwide, which was 8.3% 0f chronic diseases. In India, chronic respiratory 
diseases were found to be the reason for 7% of deaths, and DALYs lost were 
3%.3 
 Exacerbations seen in these diseases are associated with greater and 
irreversible decline in lung function, significant mortality and morbidity.4 
Almost 75 to 80% of infections seen in these diseases were bacterial and 
viral pathogens. Frequently associated bacteria involved in exacerbations 
include Haemophilus influenzae, Streptococcus pneumoniae, Moraxella 
catarrhalis.3 
Infections are most frequent cause of exacerbations.4 Making an earlier 
diagnosis and usage of appropriate antimicrobials is a must for management of 
these patients.  Diagnosis by way of sputum culture is seen in less than 50% of 
patients with pneumonia.5  
Lower respiratory tract infections produce between 5 to 10 % of all deaths 
reported to the CDC via Mortality Reporting System as per WHO. 
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Clinically visible chronic respiratory diseases are the ones usually 
diagnosed rather than the hidden entities. This can hamper the exact prevalence 
and morbidity data, which can show underestimated values of these diseases. 
Thereby it is difficult to formulate policies of prevention, diagnosis and 
treatment of chronic respiratory diseases in the population. So we need to 
standardize disease definition, have improved monitoring and a time bound 
proper surveillance. 
Bacterial colonization of the distal airways, though poorly understood, 
can worsen the underlying disease. The constant presence of microorganisms 
in the distal airways can lead to severe progression of the conditions. We need 
to know the type of colonizing microbial agents, which can help in devising 
antibiotic protocols for treating these conditions affecting the lower respiratory 
tract. This has envisaged the importance of acquiring the quantitative invasive 
procedure like BAL for identifying the pathogen and aiding in their diagnosis 
and management. 
With the arrival of bronchoscopy and quantitative invasive techniques 
like Bronchoalveolar lavage showed a marked improvement in the sensitivity 
and specificity of these diagnostic techniques in detection of pulmonary 
pathogens.6 
BAL has the dual advantage of being the most appropriate one for most of 
the microbiological procedures, and usually has adequate volume to perform 
multiple tests. The procedure has become easily accessible to the community 
and is available at an affordable cost.  
This study was done on patients of chronic respiratory diseases who 
underwent BAL, which was processed in the central diagnostic laboratory, 
department of microbiology and the results obtained were analyzed.                          
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                                                         AIM OF STUDY 
 
 
 To detect pathogenic organism by microscopical examination of 
Bronchoalveolar lavage specimens. 
 To isolate and identify aerobic bacteria and fungus from 
Bronchoalveolar lavage specimens. 
 To determine antimicrobial susceptibility pattern of the bacterial 
isolates. 
 To determine the molecular characterization of the commonest 
isolated organism by Polymerase Chain Reaction. 
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REVIEW OF LITERATURE 
 
Historical review: 
BAL is an important procedure in identifying pulmonary diseases, ever 
since rigid bronchoscopy was done by Jackson in the year 1904. Initially BAL 
was used to treat patients with diseases causing productive secretions like 
alveolar proteinosis, cystic fibrosis and bacterial pneumonia.  
BAL had two types, one was large volume and the other was small 
volume. Large volume was made up of saline 15 to 30 liters which was 
instilled in a two to three hour period of time to clear the lungs of its secretion. 
This was called as bronchioalveolar debridement. Small volume was instilling 
300 ml of saline and clearing the lung. This was introduced in 1960s. It was a 
safe method and found to provide good information about the cellularity of the 
fluid content.  
Flexible bronchoscope came in the 1970s, following which there was a 
high level of usage of the equipment and BAL. This helped in lot of research 
and numerous publications followed this between 1970 and 1990. Currently 
research activities are undertaken with publications of approximately 500 in 
number per year. 
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CHRONIC RESPIRATORY DISEASES1 
Chronic diseases contributes to a huge share of premature adult deaths all 
over the world. Inspite of the magnitude of the problems these conditions are 
not very importance in the global arena. WHO’s data on chronic diseases 
indicates urgent need for prevention and control.   
The economic burden caused by chronic respiratory disease is a matter of 
concern due to its effect on occupational lung diseases. Diseases like asthma, 
respiratory allergies, COPD, occupational lung disease, sleep apnea are 
categorized as preventable chronic respiratory diseases. They cause a major 
health problem especially in low and middle income countries. 
 
MAJOR RISK FACTORS1 
1. Tobacco smoking. 
2. Air pollution. 
3. Allergens. 
4. Occupational agents. 
 
LIST OF CHRONIC RESPIRATORY DISEASES1 
• Asthma 
• COPD 
• Chronic bronchitis 
• Emphysema 
• Bronchiectasis 
• Hypersensitivity pneumonitis 
• Chronic rhinosinusitis 
• Lung carcinoma 
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• Neoplasm’s of respiratory and intra thoracic organs. 
• Lung fibrosis 
• Chronic pleural diseases 
• Pulmonary eosinophilia 
• Pneumoconiosis 
• Pulmonary heart disease 
• Pulmonary embolism 
• Pulmonary hypertension 
• Cor pulmonale 
• Rhinitis 
• Sarcoidosis 
• Sleep apnea syndrome  
 
SIGNS AND SYMPTOMS 
Haemorrhage from the airway passage 
• Haemoptysis 
• Epistaxis 
• Cough 
• Abnormal sputum 
• Dyspnoea 
• Abnormal breathing 
• Stridor 
• Wheezing 
• Sneezing 
• Hyperventilation 
• Pain in the chest 
• Pleurisy 
• Respiratory arrest 
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Asthma1 
Asthma is a chronic inflammatory condition of the airway associated 
with airway hyper-response and variable airflow obstruction that is reversible 
either spontaneously or under treatment. Allergen sensitization is an important 
risk factor for asthma and it is associated with rhinitis. 
 
Chronic Obstructive Pulmonary Disease.1 
COPD is a heterogeneous disease with various clinical presentations. 
The basic abnormality in all patients with COPD is airflow limitation. Global 
Initiative for Obstructive Lung Diseases  have defined the disease based on 
spirometric criteria by using the post-bronchodilator forced expiratory volume 
in one second and its ratio to the forced vital capacity. The main criterion for 
COPD is a FEV1/FVC ratio <70%. At present chronic bronchitis and 
emphysema are different entities and not part of COPD. 
 
Chronic Bronchitis1 
Clinical definition 
Chronic productive cough for three months in each of two consecutive 
years in a patient in whom other causes of productive chronic cough have been 
excluded. 
 
Emphysema1 
Anatomical definition 
Permanent enlargement of the air spaces distal to the terminal 
bronchioles, accompanied by destruction of their walls without obvious 
fibrosis. 
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Pulmonary Hypertension1 
Pulmonary hypertension is defined as a mean pulmonary artery pressure 
above 25 mm Hg. If untreated, this condition has a poor prognosis. This 
condition complicates other lung conditions like bronchiectasis, cystic fibrosis 
and COPD. 
 
Epidemiology1 
Chronic respiratory diseases affect less than 25 % of the population 
globally. This data is obtained mainly from high income countries. It is 
expected that number of cases will increase in the low and middle income 
countries. At present the available data on risk factors, burden and surveillance 
of chronic respiratory diseases are incomplete and fragmented. 
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Figure I 
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Infections of the Respiratory Tract31 
The respiratory tract is divided into Upper Respiratory Tract and Lower 
Respiratory Tract. The upper airway starts from nose, throat, oropharynx and 
nasopharynx. The lower airway begins from larynx, trachea, bronchi, 
bronchioles and alveolar air sacs. 
 
Infections of the Upper Respiratory Tract31 
The oropharyngeal flora of normal individual is comprised of  
Bacteria 
Viridans streptococci, 
Β-hemolytic streptococci, 
Staphylococcus aureus, 
Haemophilus influenza, 
Streptococcus pneumonia, 
Moraxella catarrhalis, 
Fusobacterium spp, 
Actinomyces israelii, 
Fungi 
Candidia albicans. 
Virus 
Adenoviruses, 
Herpes simplex virus. 
 
In patient who are sick and hospitalized the indigenous flora switches 
from gram-positive to gram-negative in the upper airway. 
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Infection of the Lower Respiratory Tract.31 
The lower respiratory tract consists of all structures below the larynx. 
Trachea (tracheitis). 
Bronchi (Bronchitis). 
Bronchioles (Bronchiolitis) and  
Distal air spaces (Pneumonia). 
 
Pneumonia 
The most serious infection of the respiratory tract is pneumonia, which 
is centered on the distal air spaces from the alveolar ducts to the alveolar sacs. 
 
Definition 
“Pneumonia is defined as a new, progressive or persistent (more than 24 
hours) infiltrate on a chest radiograph when two or more of the following 
criteria were met. 
macroscopic purulent sputum, temperature of more than 38.5°C or less 
than 36.5°C, leukocytosis of 10,000 cells/µL or more, or leukopenia of less 
than 4,000 cells/µl and dyspnea or worsening of respiratory status.” 
 
Symptoms 
Fever, 
Cough, 
Sputum production and  
Chest pain 
Types 
Atypical pneumonia. 
Acute pneumonia and  
Chronic pneumonia. 
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Specimens to Culture 
Sputum. 
Blood. 
Bronchoscopy secretions. 
Transtracheal aspirate. 
Lung aspirates . 
Biopsy. 
 
Bacterial species potentially associated with infections31 
Streptococcus pneumonia 
Haemophilus influnzae 
Staphylococcus aureus 
Klebsiella pneumonia and other Enterobacteriaceae 
Moraxella catarrhalis 
Legionella spp 
Mycobacterium spp 
Fusobacterium nucleatum 
Prevotella melaninogenicus 
Bordetella species. 
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BRONCHOSCOPY 
Definition: 
It is a technique of visualizing the inside of the airways for diagnostic and 
therapeutic purposes by using a bronchoscope.34 
There are basically two types of  bronchoscopy. First one is a rigid 
bronchoscopy and associated with a lot of complications. The second one is the 
flexible fibre optic bronchoscopy. This type is flexible and has fewer 
complications. 
Bronchoscopy has both diagnostic and therapeutic uses in the field of 
medicine. Some of the diagnostic uses are to find the cause of haemoptysis, 
wheezing and uuexplained cough of more than 4 weeks duration. If 
radiological image is suggestive of atelectasis of segment, lobe or the entire 
lung. If there is a radiological opacity which is localized to a segment or lobe 
of the lung. It is indicated in obstructive emphysema to rule out any forgien 
bodies in the lung. To diagnose the cause of hilar and mediastinal shadows. To 
find out the reason for vocal palsy. Another main use is collecting bronchial 
secretions for bacterial and fungal culture and antimicrobial susceptibility 
testing. It is therapeutically used in the removal of foreign bodies, secretions 
and mucus. 
Bronchoscopy is contraindicated in some condition. The procedure cannot 
be performed when proper oxygenation is not possible during scopy. It cannot 
be performed when the patient suffers from non treatable coagulation 
disorders. In conditions like marked kyphosis and aneurysm of thoracic aorta. 
New diagnosed myocardial infarction and unstable angina patients cannot 
undergo bronchoscopy. Lastly bronchoscopy cannot be done on respiratory 
failure patients requiring assisted ventilation.  
Complication related to bronchoscopy are dental injuries, edema of the 
larynx, bleeding from the site of biopsy and lastly hypoxia and cardiac arrest. 
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FIGURE II - Flexible fibre optic bronchoscopy 
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Advantages of Flexible Fibre Optic Bronchoscopy 
• Provides magnification and better illumination. 
• Smaller size permits examination of subsegmental bronchi. 
• Easy to use in patients with neck or jaw abnormalities. 
• Can be performed under topical anaesthesia and useful for bedside 
examination of critically ill patients. 
• Suction and biopsy channel provided helps to remove secretions, mucus 
plugs and small foreign bodies. 
• Can be easily passed through endotracheal tube and in tracheostomy 
opening. 
 
BRONCHOSCOPY SPECIMENS.35 
Bronchial washing 
Bronchial washings are the secretions aspirated at the back channel of 
the bronchoscope, after instillation of saline into a major respiratory passage. 
Bronchial brushings  
Bronchial brushings are exclusively used for exfoliative cytology which 
aids in the diagnosis of malignancy. Bronchial brush is prone for 
contamination during insertion into the bronchoscope, hence not an ideal 
material for bacterial cultures. 
Bronchoalveolar lavage 
BAL requires careful manipulation of the bronchoscope into the 
airways. Thereby it can reach the particular airway with ease. Here a large 
volume usually 140 milliliters provided in 3 to 4 aliquots is pushed into the 
lumen of the airway and the aspirated large volume can be used to sample the 
secretions and fluid of the distal segments of the airway.36,37  
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Commensal Flora of Respiratory tract.31 
α/γ-Hemolytic streptococci 
β-Hemolytic Steptococci, other than group A 
Candida spp. 
Coagulase-negative staphylococcus. 
Corynebacterium spp. (diphtheroids) 
Haemophilus parainfluenza 
Neisseria spp. 
Pathogens of Respiratory tract.31 
Adeno virus 
Anaerobes (as part of mixed infection) 
Bordetella pertussis 
Chlamydia pneumonia 
Chlamydia psittaci 
Corynebacterium diptheriae 
Cryptococcus neoformans 
Cytomegalovirus 
Enterobacteriaceae 
Haemophilus influenza 
Herpes simplex virus 
Legionella spp. 
Moraxella catarrhalis 
Mycobacterium spp. 
Mycoplasma pneumonia 
Myxoviruses and paramyxoviruses 
Neisseria gonorrhoeae 
Neisseria meningitides 
Pneumocystis jivovecii 
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Pseudomonas aeruginosa 
Stahylococcus aureus 
Streptococcus pneumoniae 
Streptococcus pyogenes (group A) 
 
BRONCHOSCOPIC SPECIMENS 
General characteristics.  
Bronchoscopy  produces several types of specimens for analysis. Here 
qualitatively and quantatively they must be taken into consideration for 
handing in a appropriate way for each. They is a high possibility of 
contaminations while passing through different anatomical site right from the 
upper respiratory tract to the lower respiratory tract.59 
There is a possibility for yielding a true pathogen even in a mixed 
secretion which can pose a problem in analysis and interpretation of the 
specimens. Brushing samples are very limited, so the number of test performed 
on it are also less. Whereas with large volume lavage the samples are usually 
sufficient for multiple tests and analysis.63 
Multiple types of specimen can be obtained by a single bronchoscopic 
procedure and the information obtained may complement each other. Types of 
specimens differ based on the clinical conditions suspected.64 
In HIV positive cases commonly obtained specimen is BAL, TBB can 
add some more information in this sutiation. When bacterial pneumonia is 
suspected PBS samples is obtained. In other immunocompromised conditions 
BAL with PBS is obtained. TBB plays a vital role in proving tissue invasion of 
herpesviruses and opportunistic fungus. Bilateral BAL increases the sensitivity 
of identification of pathogens like P. jirovecii and CMV.83,85 
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When VAP is suspected BAL and PBS are obtained from the 
subsegment of the lung that is affected. But there is disagree in selecting a 
specific subsegment for diagnosis. In non ventilated patients with severe 
pneumonia both BAL and PSB specimens are collected.  
 
BRONCHOALVEOLAR LAVAGE 
Definition:  
“BAL is a method for the recovery of cellular and non-cellular 
components from the lower respiratory tract (e.g. alveoli).” 
In BAL procedure bronchoscopic tip is carefully wedged into an airway 
lumen which is isolated from the rest of the central airway. Greater than 140 
milli liters of saline is injected into the lumen from 3 to 4 different aliquots. It 
is designed to sample, fluid and secretions of distal airway bronchioles and 
alveoli. An estimate of 1 million alveoli are sampled for 1 ml of actual 
pulmonary secretions returned in the total BAL fluid. There is a huge 
difference in the total return volume which ranges from 10 to100 ml.36  
Due to the large volume available BAL is appropriate for 
microbiological procedures which involves multiple tests. Protected BAL 
catheter helps in reducing contamination of the upper airway.37 
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COMPLICATIONS OF BRONCHOSCOPY 
The complication of bronchoscopy varies with condition of the illness. 
Respiratory arrest is a complication in severely ill patients with impending 
respiratory failure.38 
Other major complications of BAL are hypoxemia, pneumothorax, 
cardiac compromise and hemorrhage. The is a rare possibility of transbronchial 
spread of infection in patient undergoing BAL.39 
 
Indications for Bronchoalveolar Lavage 
BAL is a critical tools for the work up of infectious diseases. It also has 
its application on diagnostic, therapeutic and research lines. BAL is performed 
in immune competent patients suffering from chronic pneumonia, tuberculosis 
and cystic fibrosis. It can also be performed in immune compromised 
conditions like HIV infection, organ transplantation and chemotherapy.42 
BAL is also useful in evaluating non specific chronic respiratory 
symptoms, in clinical presentation suggestive of chronic interstitial lung 
disease, non specific radiological findings and diffuse parenchymal lung 
disease.  
 
Uses of BAL in diagnosis of Infections  
The conditions are as follows 
• Ventilator associated pneumonia40 
• Community acquired pneumonia41 
• Hospital acquired pneumonia 
• Mycobacterial infection of the lung 
• Aspergillus infection of the lung 
• Pneumocystis pneumonia. 
• Toxoplasma pneumonia 
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• Mycoplasma pneumonia 
• Legionella pneumonia 
• Chlamydia pneumonia 
• Viral pneumonia 
Site of lavage 
In the case of localized lesion like in lung infection the affected segment 
is lavaged. Sampling is influenced by radiologically apparent infiltration 
indicating the segment involved. The middle lobe or lingual is the most 
preferred site for lavage in diffused lung disease. The reasons are that the site 
is anatomically more accessible and the fluid of this one site represents the 
whole lung. Using this method, approximately 1.5 – 3 % of the lung are 
sampled. This amounts to sampling 100000 alveoli. 
Fluid used 
Sterile normal saline is used in performing lavage. It is preferable to 
used the saline at 37˚C which is equal to our body temperature. This precaution 
helps prevent cough in patients. The volume of sterile saline varies between 
100 ml and 300 ml in aliquots of 20 to 50 ml capacity.  
Fluid instillation and recovery 
The fibro optic bronchoscope is wedged into a sub segmental bronchus. 
The fluid is instilled through the bronchoscope and almost immediately 
recovered by applying suction of 25-100 mmHg. Each aliquot is aspired into a 
separate syringe. Recovered aliquots are consecutively numbered.  
In health individuals 60-70 % of the volume may be recovered. In 
patients with underlying pulmonary disease, the recovery rate is lower. 
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Factors affecting composition of BAL 
Many factors can influence the quality and composition of BAL samples, 
including the total volume of saline instilled and the length of the dwell time 
between saline instillation and withdrawal, because ELF can be diluted by 
fluid exchange occurring between alveolar, vascular, and interstitial 
compartments.  
The BAL sample should be considered adequate if there is 40% recovery 
of instilled fluid, ,5% epithelial cells and minimal amounts of mucus after 
filtering. 
There is no reliable indicator to calculate the proportion of BAL fluid that 
represents ELF, which makes comparison between research studies difficult.  
 
Guidelines for transport BAL.43 
Saline solution of BAL should be transported in sterile, leak proof and 
non adherent container.44 Potential use of sample is to identify strict pathogens 
of the lower respiratory tract. Designated personal in a laboratory should be 
responsible for dividing the sample aseptically for appropriate tests. BAL 
should be transported in specific transport media for diagnosis of mycoplasma, 
chalmydiae and viruses.46 
Undue delay in transport should be avoided to prevent over growth of 
colonizing and contaminating organisms.48This will also help prevent decline 
of fastidious pathogens. 30 minutes is the optimal time and 2 hours at room 
temperature is the upper limit for transporting respiratory samples for 
processing bacterial pathogens excluding anaerobes. For isolation of 
anaerobes, BAL should be transported in anaerobic media and processed 
within 30 minutes.45 
For fungal and mycobacterium, refrigeration for prolonged time is 
acceptable.47 
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Specimen Handling 
Bronchoscopic specimens should be handled with clearly defined 
guidelines. Guidelines should cover specimen preparation, staining techniques, 
smear interpretation, culture techniques and culture interpretation.52 
Minimum accepted volume for BAL is 10 ml for comprehensive 
microbiological analysis. Quantitative culture is performed directly from the 
fluid. BAL is centrifuged for other tests.49 
 
Processing of BAL 
BAL fluid is processed immediately upon arrival at the laboratory. Since 
the first aliquot is usually poorly recovered and reflects a disproportionate 
amount of bronchial material, this fraction is used for mycobacterial 
investigation.50 
 Other fractions are pooled and processed. Equal parts of fractions are 
pooled and used for further investigation, such as total cell count, cytospin 
preparations and quantitative culture. 
 When indicated additional tests can be included like detection of fungi, 
Legionella pneumophillia, viruses, detection of Mycoplasma pneumonia and 
Chlamydia pneumonia by means of polymerase chain reaction.51 
 
Quality control of BAL 
To ensure that the obtained material represents the situation in the 
alveoli, a number of criteria have been established. 
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 A BAL fluid is regarded non-representative if one of the following criteria 
is seen: 
• Volume less than 20 ml. 
• Total cell count less than 60,000 cells/ml. 
• Presence of more than 1% squamous epithelial cells. 
• Presence of more 5 % bronchial epithelial cells. 
• Presence of extensive amounts of debris. 
• Severely damaged cell morphology. 
 
DIRECT MICROSCOPY OF BAL 
Direct microscopy may be viewed as three distinct categories:49 
• Stains for cytological assessment,  
• Stains for general organism categories and  
• Stains for specific organism types. 
 
Cytological assessment. 
BAL sample histopathology detects cell changes due to viral infection 
and invasive fungal infections. To assess oropharyngeal contamination of BAL 
the relative numbers of inflammatory cells and squamous epithelial cells are 
examined by Gram stain. Increase in the percentage of neurophils and 
lymphocytes is noted in infectious conditions. Elastin fibers are noted in 
necrotizing pneumonia.53 
 
Organism detection  
Different staining procedures are used in detection of organism. Gram 
staining is frequently employed for bacterias. It provides quick information on 
morphology of the bacteria which provides valuable information in the initial 
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selection of antibiotics.54  For the detection of Mycobacterium spp. Stains like 
carbol fuchsin based acid fast stain and auramine rhodamine are used. 
Modified acid fast stain is used in the identification Nocardia spp. Cell wall 
stains like methenamine silver and calcofluor white is used in the identification 
of Pneumocystic jirovecii and fungus.55 
 
Specific stains  
DFA staining is used for detection of Legionella, Pneumocystis 
jirovecii, respiratory viruses, CMV and Herpes simplex virus.57 
 
OVERVIEW OF LABORATORY METHODS 
Bronchoscopic specimens microbiological analysis is made complicated 
due to reasons like pathology of infectious lung diseases and practical 
difficulties of specimen handling.58 
Firstly the etiological agents belong to a large group, comprising of all 
major categories of microorganism. So the laboratory must be prepared to 
identify the vast number of organisms by employing a number of different 
procedures. Many infections are polymicrobial in nature and necessitates to 
perform multiple analysis on the specimen.60 
Secondly, even when careful bronchoscopic techniques are used, the 
analysis of specimens is confounded by the inevitable presence of colonizing 
organisms that may also be etiologic agents of disease in the respiratory tract 
of seriously ill patients.  To differentiate colonization from infection, the 
laboratory must employ quantitative culture techniques.59 
Thirdly, because of the clinical need for timely institution of specific 
therapy, special emphasis is placed on the availability of tests with rapid 
turnaround times, especially direct microscopy.68  
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Rapid processing of specimens for culture is also desirable to prevent loss 
of viability of pathogens or overgrowth of contaminants in these unpreserved 
specimen types.67 
Finally, the renewed emphasis on cost containment in the era of managed 
competition challenges the laboratory to accomplish all of these tasks in a cost 
effective manner.56 
 
Microbiologic Spectrum 
An overview of the microorganisms that may be etiologic agents of 
lower respiratory tract infection in adults in the clinical settings in which 
bronchoscopy is frequently performed is given below as a table. 
 
Gram positive aerobic bacteria Staphylococcus aureus, Streptococcus 
pneumonia and Viridans group 
Gram negative aerobic bacteria Pseudomonas aeruginosa, Acinetobacter 
spp., Enterobacter spp., Klebsiella spp., 
Moraxella catarrhalis, Haemophilus 
influenza. 
Viruses Herpes virus, Respiratory viruses. 
Fungi Cryptococcus neoformans, Candida spp., 
Histoplasma capsulatum, Blastomyces 
dermatitidis, Coccidioides immitis, 
Sporothrix schenkii, Aspergillus spp., 
Pneumocystis jirovecii 
Protozoa Toxoplasma gondii, Leishmania spp., 
Microspordia, Cryptosporidium parvam,  
Helminths Strongyloides stercoralis. 
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Organisms of the lung are classified into two groups. Some organisms are 
considered pathogens of the lung and the others are considered as colonizing 
flora of the respiratory system. Later organisms present in the respiratory 
secretions pose technical difficult in detection. This difficult can be minimized 
by careful selection of specimens, collection and critical interpretation of the 
findings. 
Strict pathogens which does not pose difficult in diagnosis are Legionella 
spp., Mycoplasma pneumoniae, Chlamydia spp., Nocardia spp., 
Mycobacterium tuberculosis, Francisella spp., Bordetella spp., systemic 
dimorphic fungi, Seasonal respiratory viruses, Protozoans and helminthes.61 
Careful clinical assessment at times can predict the etiologically agent in 
a given patient. But there is significant overlaps in the clinical features 
imposing the need of laboratory processing of respiratory samples for detection 
of the pathological agents.59 
In 30 to 60 % of cases suspected of pneumonia no specific etiological 
organism  is identified even with an extensive battery of non invasive tests 
done. In this scenario, if bronchoscopy is incorporated with well defined 
diagnostic protocol than the percentage of identification of pathogens rise to 80 
to 90 %. So total diagnostic yield of bronchoscopy is greater in comparison 
with non invasive methods.62 
. 
 
Stains performed on BAL fluid 
Application of BAL fluid in the diagnosis of pulmonary infections has 
been proven to be very useful. A number of stains are routinely performed on 
BAL fluid samples. These includes the Gram-stain and May-Grunwald Giemsa 
stain. 
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 Besides the standard stains, a number of stains can be added to the 
investigation upon clinical indication.  
For example:   
Grocott methenamine-silver for fungi and pneumocystis jiroveci. 
Auramine-Rhodamine, Ziehl-Neelsen  for acid-fast bacteria. 
Legionella immunofluorescence for Legionella spp. 
Acridine-organe for microorganism in general. 
BAL culture procedures 
 For most organisms, culture remains the definitive diagnostic method. 
 
Basis of quantitative culture 
 Quantitative culture method is employed there to differentiate pathogens 
from contaminants as it is difficult to avoid oropharyngeal contamination 
during collection of BAL.37,67 
 
 
Quantitative culture methods 
It is the gold standard method in the diagnosis of pneumonia in BAL 
sample. BAL fluid represents the situation of alveoli by 10 to 100 times.49 
Two methods are employed for quantitative culture of BAL. One is the 
serial dilution method where two 100 fold dilution from 0.1 ml sample are 
spread on surface of the agar plate. Counts are obtained from the plate with 
more number of colonies and without confluent growth. Reported as cfu per 
Pathogens More than 105  CFU/ml 
Contaminants Less than 104 CFU/ml 
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ml.7 Second method is calibrated loop method and this method is very easy and 
practical. This method is similar to urine culture and 0.001 or 0.01 ml is 
suitable for BAL sample. Results are given as log10  ranges.70 
 
Quantitative culture interpretation 
In both type of procedures, each colony types should be separately 
quantitated and reported. The identification of the organisms and antimicrobial 
susceptibility testing should be decided based on the quantitaion of the 
organisms. Colonies which are less than the cut off value should be considered 
contaminants.69 
Positive quantitative bacterial culture from BAL fluid 
 A positive quantitative culture was defined as  more than105 cfu/ml of 
Bacteria from BAL sample.37 
Diagnostic methods employed in detection of various microorganisms in 
BAL fluid 
 For the identifications of Bacteria Gram’s staining and Quantitative 
bacterial cultures are used. Chlamydial infections are detected by direct 
immunoassay, culture and molecular methods. Fungi like pneumocystis 
jiverocii is identified by staining methods like Gomori-Grocott, Toludine blue 
and Wright-Giemsa stains. Other methods which are of use are direct 
immunoassay and Molecular methods. 
 Other fungus are identified by Gram’s stain, Gomori-Grocott, culture 
and direct immunoassay. 
 Legionella infections are diagnosed by Gomori-Grocott staining, direct 
immunoassay, culture and molecular methods. Infections caused by 
mycobacterium are detected by Auramine-rhodamine staining, Zielh-Neelsen 
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staining, culture and molecular methods. Mycoplasma is identified by 
Immunoassay, culture and molecular methods. 
Viruses like Cytomegalovirus, Herpes simplex virus are identified by 
cytopathic effect in tissue culture, inclusion bodies, direct immunoassay, 
culture, electron microscopy and molecular methods. 
Disc diffusion methods of antimicrobial sensitivity testing.33 
These methods are suitable for organisms that grow rapidly overnight at 
35-37˚C. The antibiotic-impregnated disc adsorbs moisture from the agar and 
antibiotic diffuses into the agar medium. The rate of extraction of the antibiotic 
from the disc is greater than the rate of diffusion. As the distance increases, 
there is a logarithmic reduction in the antibiotic concentration. 
The extent of antibiotic diffusion is affected by the depth of the agar. 
Visible growth of the bacteria occurs on the surface of the agar where the 
concentration of the antibiotic has fallen below its inhibitory level for the test 
strain.  
The time required to reach the critical cell mass (4 to 10 hours) is 
characteristic of each species but is influenced by the media composition and 
incubation time. The point at which the critical cell mass is reached appears as 
a circle of bacterial growth, with the middle of the antibiotic disc forming the 
centre of the circle. 
There is no single internationally accepted method of disc diffusion 
testing. In the USA a modification of the Kirby-Bauer (Bauer et al 1966) 
method is used. This method is recommended by the CLSI and WHO. 
Standardization of the technique controls variation, and interpretation is by 
comparison of inhibition zones with published tables of critical zone diameter. 
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     In Europe, guidelines for diffusion methods are available from the 
European Committee for Clinical Laboratory Standards. Rigid standardization 
of technique is published regression lines that plot MICs for strains of different 
species against the zone diameter produced by a disc of the strength used in the 
test. The validity of this method is controversial. 
 
Specific etiologic agents 
Based on the specific agents of etiology, bronchoscopy as a varying 
indication in the process of diagnosis. Bronchoscopy is the first line procedure 
in some cases and bronchoscopy plays a secondary role when there is a failure 
in empirical therapy and inability to identify the causative agent by non 
invasive techniques.  
 
Bacterial Pathogens 
Aerobic bacteria  
Gram staining and quantitative culture of BAL has become an important 
tool for the diagnosis of pneumonia caused by aerobic bacteria. When 106 
cfu/ml is used as the threshold  for BAL quantitative culture the sensitivity 
increases.71  
 
Anaerobes  
Role of bronchoscopy for diagnosis of anaerobic infections is not 
established beyond doubt. Studies are needed in this area to establish the 
significance of bronchoscopy.72,73  
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Legionella spp.  
In conditions like hospital acquired pneumonia, CAP and transplant 
cases Legionella has been identified as important lung pathogen. 
Bronchoscopy is used in this conditions due to absence of sputum production.74 
Increased number of polymorphonuclear cells in respiratory secretions with the 
absence of recognizable morphotype is indicative of  legionellosis. BAL 
specimen is useful in rapid diagnosis of Legionella by DFA staining.75 
 
Nocardia spp  
BAL is identified as a useful specimen in the diagnosis of Nocardia as 
important lung pathogen in groups like immunocompromised and organ 
transplantation cases.76 The organism is identified microscopically gram 
positive, branching with beaded filaments. They are acid fast to weak acid 
decolorizer.Charcoal-yeast extract medium is used as culture media for 
primary isolation of Nocardia.77 
 
 
Mycoplasmas 
Knowledge in use of bronchoscopic samples for diagnosis of 
mycoplasma pneumonia is very much limited due to reasons like diffuiculty in 
culturing the organism and lack of alternative methods ilke direct specimen. 
BAL sample isolation of Mycoplasma pneumonia is seen in conditions like 
Community acquired pneumonia and pneumonia in immune suppressed 
patients.79 
The commonest specimen used are swabs of upper respiratory system. 
There is no study comparing BAL and upper respiratory swab.78 
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Chlamydia spp  
BAL isolation of Chlamydia pneumonia in clinical setting like hospital 
acquired infection and HIV cases has been successful. Culture of this organism 
is difficult due to the need of special transport media, suitable cell culture and 
specific reagents. So serological diagnosis can be used as an additive to 
culture. Study by Gaydos et al reported 12 PCR positive from 132 culture 
negative BAL specimens from immune suppressed cases. This observation 
proves PCR is more sensitive than culture.80   
 
Mycobacterial Infections 
Bronchoscopy has proven useful in sputum smear and culture negative 
with atypical presentation where the clinical suspicion is very high like in the 
case of military disease. BAL and Bronchial washing were observed to have 
similar sensitivity in the diannosis. Since new culture methods provide rapid 
results than conventional culture methods, it s unclear when to perform 
bronchoscopy as a diagnostic procedure.81 
 
 
Mycobacteria other than M. tuberculosis  
Mycobacterium kansasii is clinically significant and difficult to isolate 
form respiratory secretions. Upper airway colonization is present with 
Mycobacterium avium complex in HIV patients and Mycobacterium fortuitum 
in intensive care unit patients. BAL with TBB if performed gives maximum 
diagnostic yield. Studies show BACTEC system for isolation of 
Mycobacterium from bronchoscopy specimen provides increase in the 
isolation.82  
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Pneumocystis jirovecii 
Bronschoscopy has been accepted as a definitve diagnostic method for 
Pneumocystic jirovecii due to AIDS epidemic and recognition of Pneumocystis 
jirovecii as lung pathogen. BAL had 82% sensitivity when compared with 
brushing and washing which was only 53% sensitive. BAL sample of bilateral 
lavage procedure has greater sensitivity when compared with unilateral Bal 
sample. Induced sputum a non invasive alternative to BAL had sensitive 
ranging from 15 % to 100 %.83 
 
Common staining techniques of Bronchoscopic specimens used in the 
detection of Pneunocystic jiverocii cyst are Gomori’s methenamine silver, 
Gram-Wiegert, Toluidine blue O and calcofluor white. For the detection of 
trophozoites and intracycstic bodies modified Wright-Giemsa method is used. 
 
 
Viral Infections 
Common respiratory viruses.  
A role for bronchoscopy in detection of common, seasonal respiratory 
viruses like respiratory syncytial virus, parainfluenza viruses, and influenza 
viruses is not well established. Nasopharyngeal, tracheal swab and aspirates 
are preferred respiratory samples for culture and antidetection in viral 
infection. 
Viruses can be detected in bronchoscopic samples of  severely ill patients 
suspected with suspection of non bacterial pneumonia. Laboratories should be 
equipped to detect viruses from bronchoscopic samples in epidemic suitations. 
Viruses can be identified from BAL by culture, DFA and antigen detection.84 
Cytopathological changes of BAL cells may help in the recognition of 
respiratory syncytial virus. Cytopathological changes and culture of 
bronchoscopic samples have demonstrated adenovirus and measles virus. 
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Latent viruses  
It is most challenging to diagnose latent viruses like herpes and the 
interpretation of the lab results becomes moer difficult in immune 
compromised setting. In bronchoscopic specimens CMV poses challenges, due 
to immune suppression of cell mediated immunity reactivates latent infections. 
CMV is reported to be frequently associated with pneumonia in organ 
transplantation and HIV infection.85 
 
CMV.  
CMV pneumonitis manifest as a mild focal interstitial process to severe 
diffuse alveolar damage. Bilateral BAL  sample increases the sensitivity of 
diagnosing CMV infection. BAL offers addition advantage of diagnosing other 
opportunistic pathogens since CMV coexists with other pathogens. Since CMV 
frequently coexists with other pathogens, BAL offers the added advantage of 
the opportunity to detect other pathogens. Methods like cytopathology, DFA, 
culture and in situ hybridization are employed to detect CMV for BAL. Of the 
above methods culture is more sensitive.  
 
 
HSV.  
HSV is present in respiratory secretions of immune suppressed 
individuals and oropharynx of severely ill cases with pneumonia. Pneumonia 
in HSV spreads from contiguous mode and less common by hematogenous 
route to lung. Due to the above reasons HSV may be a pathogen or 
contaminant in bronchoscopic samples. 
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Other latent viruses 
Lymphocytic interstial pneumonitis is associated with HIV and Epstein- 
Barr virus. 
Bronchoscopic samples role is not well documented in the diagnosis of 
these conditions.85 
 
Protozoans and Helminths 
Bronchoscopic samples demonstrates unusal parasites occasional in 
immune compromised host. The diagnostic ability of the microbiologist paly 
an important role in identifying such parasites. Since pneumonia is associated 
with disseminated infection in such conditions other lab investigations like 
stool examination and serology should be done as indicated.  
 
Toxoplasma gondii 
BAL sample proves to be useful in the diagnosis of pulmonary 
toxoplasmosis. Staining methods like Wright-Giemsa are used to demonstrate 
intra and extracellular tachyzoites. As the organism as can be easily missed to 
it important to examine under oil immersion. Most of the disease in 
immunocompromised hosts is due to reactivation odf the organism dormant in 
cysts, serological tests can be made use for screening in high risk cases.86 
 
Other protozoans  
Many other protozoans of opportunistic nature has been noted in 
bronchoscopic samples. In HIV-infected cases intracellular Leishmania 
amastigotes were demonstrated in alveolar macrophages of BAL samples for 
endemic areas. By using acid-fast and specific DFA stains Cryptosporidium 
cysts was identified in bronchoscopic samples. Large numbers of 
microsporidia was demonstrated in BAL samples by special chromotrope stain 
in HIV cases.87 
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Strongyloides stercoralis  
Immunocompromised cases with hyperinfection syndrome may present 
with Strongyloides stercoralis filariform larvae in respiratory secretions. Low 
power examination of BAL sample with any stained material can demonstrate 
the larvae.88 
 
Other helminths  
Ovas Paragonimus westermani has been noticed in the sputa of 
suspected causes of tuberculosis in south East Asia. Rarely other helminthes 
have been reported in respiratory samples.89 
 
 
FUNGAL INFECTIONS 
Systemic fungal infection 
In respiratory secretions isolations of any systemic or dimorphic fungus 
has clinical significations. If possible, first non invasive specimens should be 
evaluated. If results are negative than bronchoscopic specimen can be test if 
there is a strong clinical suspicion.91 
Sputum has a low sensitivity in detection of fungi in smear and culture 
when compaired with bronchoscopic specimen. Tissue diagnosis may be 
required to confirm systemic fungal infection. BAL in predominantly 
immuncocompromised conditions yields 85 to 100 % sensitive in recent 
studies. This make BAL a preferred bronchoscopic specimen.90 
In any types of respiratory secretion, the microbiologist should be aware 
of distinctive microscopic morphologies of the tissue form of the fungi and 
report accordingly. As microscopic finding of fungus is not specific and 
sensitive, the following methods like isolation with appropriate selective media 
and rapid identification methods such as nucleic acid probe testings and 
exoantigen should be performed.92 
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Opportunistic fungi 
Bronchoscopic samples pose a number of interpretive problems in 
diagnosing infections produced by opportunistic yeast and filmentous fungi. 
Diagnosing filamentous fungi like aspergillus spp in bronchoscopic samples is 
a challenge due to lack of sensitivity. For the diagnosis of Aspergillus in BAL 
samples, Aspergillus antigen test and PCR test shows promising result due to 
increased sensitivity.93 
Major problems in diagnosis of Candida spp in bronchoscopic sample is 
lack of specificity and asymptomatic colonization. So 255 of all bronchoscopic 
specimens may show candid spp on smear and culture. Demonstration of yeast 
and pseudohyphae improves the microscopic specificity for candida spp.But 
final diagnosis is by demonstration of organism in tissue. Promising results are 
obtained when antigen test for candida spp is use for BAL specimens.94 
Identification of Crytococcus neoforms is more significant than other 
yeasts in bronchoscopic sample. BAL is the most useful sample for smear and 
culture of this yeast. Latex agglutination test is useful in rapid identification of 
this yeast.  
 
Molecular techniques in BAL fluid work-up 
The introduction of molecular diagnostic techniques like PCR in the work 
up of respiratory infectious diseases has increased in the recent years. These 
procedures have increased sensitivity where compared to conventional 
methods like culture and serology as a diagnostic tool. 
This property of PCR is helpful in cases where the microorganisms load is 
very low and in organisms which cab not be easily cultured. PCR is specific in 
the diagnosis due to the used of specific primers and probes. The technique is 
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universal and method is rapid when compared with culture and serology. In 
pulmonary infectious diseases different types of PCR can be employed for the 
diagnosis.  
The post PCR product in a conventional PCR are analyzed by gel 
electrophoresis, dot blot hybridization and enzyme immunoassay. In today’s 
time conventional PCR is replaced by Real time PCR. The advantage of real 
time PCR is that there is no post PCR analysis due to which results are 
obtained quickly and there is less chance of contamination.  
Real time PCR method measures the amount of amplified PCR product 
during each cycle, by which quantitative results can be obtained. This helps in 
identifying carrier state and infection. Multiple organisms can be diagnosed by 
multiplex PCR methods in a single test because respiratory pathogens cause 
same clinical symptoms. This method is cost effective but sensitivity is less 
compared to mono specific PCR. Causative organisms of pneumonia can be 
diagnosed by the above PCR methods. 
The Table below gives a list of causative organism of pneumonia for 
which PCR is described in the literature 
Bacteria Fungus Virus 
Streptococcus pneumonia Pneumocystis jirovecii Herpes simplex virus 1 
and 2 
Haemophilus influenza Aspergillus fumigates Respiratory syncytial 
virus 
Mycoplasma pneumonia 
  
Chlamydia pneumonia 
  
Legionella pneumophila 
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Molecular Characterizations of Klebsiella pneumoniae 
The majority of proteins are involved in metabolic processes, such as 
energy metabolism and transporters, supporting the general concept that the 
core genome encompasses essential functions required for survival of the 
microorganism. 
 
The Klebsiella pneumoniae core genome comprised several sets of genes 
whose functions are related to bacterial survival in the environment or 
interaction with its host,and possibly virulence. 
 
Haemolysin gene of Klebsiella pneumoniae has been cloned and 
sequenced. This peptide of approximately 200 basepair was identified.  
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MATERIALS AND METHODS 
 
APPROVAL OF THE ETHICAL COMMITTEE 
The ethical committee of this institution approved the study and 
informed consent was obtained from all patients undergoing the study. 
 
PERIOD OF STUDY 
This study was conducted over a period of one year from May 2015 to 
April 2016. 
 
PLACE OF STUDY 
It was carried out in the Department of Microbiology, Thanjavur 
Medical College. 
 
COLLABORATING DEPARTMENT 
Department of Thoracic Medicine, Thanjavur Medical College. 
 
DESIGN OF STUDY 
It was a prospective observation study. 
 
STATISTICAL ANALYSIS 
 Data collected will be analyzed using descriptive statistical methods by 
computing Percentage, mean and standard deviation. Wherever necessary the 
results were depicted in the form of percentages. 
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MATERIALS 
This study included 100 patients (men and women above 18 years) who 
underwent bronchoscopy. 
 
INCLUSION CRITERIA 
1. Adult patients with Chronic Respiratory Diseases undergoing 
Bronchoalveolar lavage. (Age above 19 years). 
2. To identify aerobic bacteria and antimicrobial sensitive of the bacterial 
isolates. 
3. To identify fungal isolates. 
 
EXCLUSION CRITERIA 
1. Patients with unstable cardiac conditions (recent myocardial infarction, 
cardiac arrhythmia, etc.) 
2. Pregnant women. 
3. Mycobacterial culture. 
4. Patients who do not give consent for the procedure. 
Examination of Patients. 
In the Thoracic Medicine ward, patients with Chronic respiratory 
diseases where asked for history of presenting complaints like fever, cough and 
production of sputum. Duration of illness. History of any cardiac problems. 
Specimen Collection. 
Patients were instructed to stop smoking and fast for a minimum of 12 
hrs before sample collection. 
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Bronchoscopy with BAL was performed according to standardized 
procedures designed to minimize oral contamination. 
BAL was performed by sequentially instilling and then withdrawing 50 
ml aliquots of sterile normal saline. 
Bronchoalveolar lavage fluid specimens collected under aseptic 
precautions was immediately transported to the laboratory for bacterial and 
fungal processing. 
 
FIGURE –III SPEICMEN OF BAL FLUID. 
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Direct microscopy 
Centrifugation of the sample is performed for detection of bacteria and 
fungi by direct microscopy. 
Sample is subjected for direct microscopy with Wet Mount preparation 
(10 % Potassium Hydroxide). 
Smears are prepared and air dried for use of special stains like Gram’s 
stain for Bacteria and Fungus, Acid Fast staining techniques like Ziehl- 
Neelsen stain to identify Mycobacteria, Kinyoun’s technique for Nocardia, and 
May-Grunwald Giemsa stain to identify Pneumocystis and fungus. 
Bacterial culture 
For bacterial culture uncentrifuged samples were used. The sample was 
inoculated for quantitative bacterial culture using standard laboratory 
techniques on Blood agar, Chocolate agar and Mac conkey agar using a sterile 
4mm nichrome loop (0.01 ml) and incubated at 37°C for 72 hours. Colony 
count of >105 colony forming units per milliliter of BAL fluid was taken as the 
cutoff for bacterial infection. 
Fungal culture 
For fungal culture centrifuged samples were used. Sample were 
inoculated on Sabouraud’s dextrose agar for fungal culture and incubated for 4 
weeks at 37°C. 
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FIGURE IV  
Bacterial growth on Mac conkey agar by Semi quantitative  
culture method. 
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FIGURE V 
Bacterial growth on Nutrient agar plate by Semi quantitative method. 
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FIGURE VI 
Growth of Candida on Sabouraud dextrose agar. 
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FIGURE VII 
Growth of Aspergillus niger on Sabouraud dextrose agar. 
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FIGURE VIII 
Growth of Aspergillus flavus on Sabouraud dextrose agar. 
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Identification of Bacteria 
The culture plates were examined for the presence of bacterial colony 
and the growth was identified with Gram’s staining, Catalase test, oxidase test, 
hanging drop test, Biochemical reaction and carbohydrate fermentation. 
 
Antimicrobial susceptibility testing 
 
Antibiotic susceptibility testing was done for bacterial isolates by Kirby- 
Bauer’s disc diffusion method on Muller-hinton agar plate. 
 
Antimicrobial susceptibility testing was performed by agar disc diffusion 
method according to Clinical and Laboratory Standards Institute (CLSI) 
guidelines.  
The following antimicrobial agents were tested:  
Aminoglycosides- amikacin (30µg),  
β Lactamase inhibitor combination – 
Amoxicillin/Clavulanic acid (20/10µg), Piperacillin/tazobactam 
(100/10µg) 
Lincosamides- Clindamycin (2µg), 
Cephalosporins- Cefoperazone (75µg), Cefepime (30µg), 
Carbapenems- Imipenem (10µg), 
Oxazolidinones- Linezolid (30µg), 
Glycopeptides- Vancomycin (30µg). 
50 
 
 
Storage of antimicrobial discs 
Container of antimicrobial disc was refrigerated at 4 - 8˚C. β lactam 
antibiotics were stored in the freezer compartment. Imipenem when stored 
frozen remains stable til the day of use. Disc containers were brought to room 
temperature before use. After the use for antimicrobial sensitivity the antibiotic 
discs were tightly sealed and stored in a dry container. 
Preparation of turbidity standard  
Commonly used is the McFarland 0.5 standard. This contains 99.5 ml of 
1 % sulphuric acid and 0.5 ml of 1.175 % barium chloride. The solution is 
poured in the tube, tightly sealed and stored at room temperature at a dark 
place. This is comparable with bacterial suspension of 1.5 X 108 colony 
forming unit/ml. 
 Preparation of Inoculum 
For preparation of the inoculum, 3 to 5 colonies were lifted and inoculated 
in 5 ml of peptone water and incubated at 37˚C for 2 to 6 hours in order to obtain 
0.5 McFarland standard which corresponds to 150 million organism per ml. If 
more turbidity was noticed, peptone water was added to adjust it to 0.5 
McFarland’s standard. 
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Inoculation of MHA plates 
A sterile cotton swab was dipped and rotated several times within 15 
minutes of adjusting the turbidity of the inoculum. To be remove excess fluid the 
swab was pressed firmly on the inner side of the wall above the level of the 
fluid. By streaking method the dry surface of the Muller-hinton agar plate was 
swabbed. This method was repeated 2 or more times by rotating the plate to 
60˚to cover the entire surface of the plate. Finally the rim of the agar plate was 
swabbed. The plate was closed and allowed to wait for 3 t0 5 minutes for excess 
moisture to be absorbed before applying drug impregnated discs. 
Application of discs to inoculated agar plate 
 A set of predetermined battery of antimicrobial discs were tested on all 
isolates. The whole disc was placed on the agar surface and pressed to make sure 
the entire surface of the disc comes in contact with the agar. Even distribution of 
the discs were make to ensure 25 mm distance from centre to centre of discs. 
This was followed by incubation at 37˚C for 16 – 18 hrs.  
Reading and interpretation of results 
 Each plates were examined after 16 – 18 hours  for satisfactory streaking  
with uniform circular zones of  and confluent lawn of growth. The diameter of 
the zones of complete inhibition including the diameter of the discs were 
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measured. The zone was measured to the nearest millimeter using a ruler which 
was held on the back of the agar plate. The zone of inhibition size was 
interpreted by referring to CLSI guidelines and reported the organism as 
resistant, intermediate or susceptible. 
 
QUALITY CONTROL RECOMMENDATION BY CLSI 
Enterobacteriaceae 
Testing condition 
Media: Muellar-Hinton Agar by disk diffusion method. 
Inoculum: Direct colony suspension equivalent to 0.5 McFarland standards. 
Incubation : 35˚C ± 2˚C in ambient air for 16-18 hours. 
Routine Quality Control: Escherichia coli ATCC 25922 
 
Pseudomonas aeruginosa 
Testing conditions 
Media: Muellur-Hinton Agar by disk diffusion method. 
Inoculum: Direct colony suspension equivalent to 0.5 McFarland standards. 
Incubation: 35˚C ± 2˚C in ambient air for 16-18 hours. 
Routine quality control: Pseudomonas aeruginosa ATCC 27853 
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Acinetobacter spp. 
Testing conditions  
Media: Muellur-Hinton Agar by disk diffusion method. 
Inoculum: Direct colony suspension equivalent to 0.5 Mc Farland standards. 
Incubation: 35˚C ± 2˚C in ambient air for 16-18 hours. 
Routine quality control: Pseudomonas aeruginosa ATCC 27853 
Staphylococcus spp. 
Testing condition  
Media: Muellar-Hinton Agar by disk diffusion method. 
Inoculum: Direct colony suspension equivalent to 0.5 McFarland standards. 
Incubation: 35˚C ± 2˚C in ambient air for 16-18 hours. 
Routine Quality control: Staphylococcus aureus ATCC 25923 
Enterococcus spp 
Testing conditions 
Media: Muellar-Hinton agar by disk diffusion method. 
Inoculum: Direct colony suspension equivalent to 0.5 McFarland standards. 
Incubation: 35˚C ± 2˚C in ambient air for 16-18 hours. 
Routine Quality control: Staphylococcus aureus ATCC 25923 
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Streptococcus pneumonia 
Testing conditions 
Media: Muellar-Hinton Agar with 5 % sheep blood. 
Inoculation: Direct colony suspension equivalent to 0.5 McFarland standards. 
Incubation: 35˚C ± 2˚C with 5% CO2 for 20-24 hours. 
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ZONE SIZE INTERPRETATIVE CHART IN ACCORDING TO CLSI.32 
Sl.
No.
Antimicrobial 
agent Symbol 
Drug 
concentration 
(µg) 
Zone size in mm 
Resistant Intermediate Sensitive 
A. Aminoglycosides 
1. Amikacin  AK 30 ≤14 15-16 ≥17 
B. β-Lactam/β-Lactamase inhibitor combination 
1. Amoxicillin/ Clavulanic acid AU 20/10 ≤17 14-17 ≥18 
2. piperacillin/ tazobactam PT 100/10 ≤14 15-20 ≥21 
C. Lincosamides 
1. Clindamycin CY 2 
≤14 15-20 ≥21 
Staphylococcus aureus 
≤15 16-18 ≥19 
Strepotococcus pneumoniae 
D. Cephalosporins 
1. Cefoperazone CF 75 ≤15 16-20 ≥21 
2. Cefepime CPM 30 ≤14 15-17 ≥18 
E. Carbapenems 
1. Imipenem  I 10 ≤19 20-22 ≥23 
F. Oxazolidinones 
1. Linezolid LZ 30 ≤20 21-22 ≥23 
G. Glycopeptides      
1. Vancomycin VA 30 ≤14 15-17 ≥17 
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FIGURE IX  
Antimicrobioal Sensitivity Test on Meuller-Hinton Agar. 
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FIGURE – X 
Antimicrobial sensitivity test on Meullar-Hinton Blood agar for fastidious 
organisms. 
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Molecular identification 
DNA extraction 
All the isolates were grown on Muller Hinton Agar and were incubated 
for 48 hours at 37°C under aerobic conditions and the bacterial colonies were 
then used for DNA extraction. 
Molecular characterisation was done for the commonest isolated 
organism by Polymerase Chain Reaction. 
Kit used for PCR 
HELINI™ Purefast Bacterial Genomic DNA Minispin prep Kit [from 
Bacterial cultures] 
Kit components 
No. of reactions 
Catalogue Number 
25 
2007 
Lysoyme 0.5 ml 
Proteinase 0.5 ml 
Digestion buffer 5 ml 
Binding buffer 5 ml 
Elution buffer 2.5 ml 
Wash buffer-1 9 ml 
Wash buffer-2 6 ml 
Spin column with collection tube 25 
Hand book 1 
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Storage and Stability 
HELINI™ Purefast Bacterial Genomic DNA Minispin prep Kit can be 
stored for up to 6 months at room temperature (+15-+25°C). For longer 
storage, it is recommended to keep the kit at 4°C. If precipitate forms in the 
buffers during storage, it should be re-dissolved by incubating the buffers at 
37°C before use. 
Proteinase K and Lysozyme should be stored at -20ºC. 
Description 
HELINI Purefast Bacterial Genomic DNA Minispin prep Kit is designed 
for rapid and cost-effective small-scale preparation of high quality genomic 
DNA from both gram negative and positive bacteria. The kit utilizes an 
exclusive silica based membrane technology in the form of a convenient spin 
column. Each Purefast® spin column can recover up to 10µg of DNA. 
The standard procedure takes less than 30 minutes following cell lysis 
and yields purified DNA of more than 30 kb in size. Isolated DNA can be used 
directly in PCR, Southern blotting and enzymatic reactions. 
 
Principle 
Cells are lysed during a short incubation with Proteinase K in the 
presence of chaotropic salt, which immediately inactivates all nucleases. 
Cellular nucleic acids bind selectively to special glass fibres pre-packed in the 
Purefast purification filter tube. Bound nucleic acids are purified in a series of 
rapid “wash and spin” steps to remove contaminating cellular components. 
 
Finally low salt elution releases the Nucleic acids from the glass fibre. 
This sample method eliminates the need for organic solvent extractions and 
DNA precipitation, allowing for rapid purification of many samples 
simultaneously. 
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Material Required 
• Micro Pipettes Variable Volume 0.5-10µl, 10-100µl, and 100-1000µl 
• Sterile pipette tips with aerosol barrier 2-20µl, 10-100µl, and 100-1000µl 
• Disposable powder-free gloves 
• Vortex mixer / Water bath 
• Centrifuge with rotor for 1.5 ml reaction tubes 
• 1.5ml/2ml centrifuge tubes 
• Water bath 
• 100% ethanol 
 
Reagent Preparation 
Add the indicated volume of ethanol (96-100%) to Wash Buffer I 
(concentrated) and Wash Buffer II (concentrated) prior to first use: 
 Cat.No: 2007-25 prep 
 Wash buffer-1 Wash buffer-2 
Concentrated buffer 9 ml 6 ml 
Ethanol (96-100%) 6 ml 24 ml 
Total volume 15 ml 30 ml 
 
DNA Purification – Procedure 
Before starting the purification reaction, set water bath to 56ºC and warm 
up the Elution buffer to 56ºC. 
1. Suspend bacterial pellet by vortexing.  
2. Add 180µl of Digestion buffer and 20µl of Lysozyme. Gently vortex for 10 
seconds and briefly centrifuge to remove drops from inside the lid of the 
tube. 
3. Incubate at 37ºC for 15min. 
4. Add 200µl of Binding Buffer and 20µl of Proteinase K, Mix well by pulse 
vortex. 
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5. Briefly centrifuge to remove drops from inside the lid of the tube. 
6. Incubate at 56ºC for 15min. 
7. Add 200µl absolute ethanol [100%] and mix well by inverting several times. 
8. Pipette entire sample into the Purefast  spin column. Centrifuge at 8000rpm 
for 1 min. Discard the flow-through and place the column back into the 
same collection tube. 
9. Add 500µl of Wash buffer-1 [ethanol added] to the Purefast spin column. 
Centrifuge at 10000rpm for 1 min and discard the flow-through. Place the 
column back into the same collection tube. 
10. Add 500µl of Wash buffer-2 [ethanol added] to the Purefast spin column. 
Centrifuge at 10000rpm for 1 min and discard the flow-through. Place the 
column back into the same collection tube. 
11. Repeat wash buffer-2 once. 
12. Empty centrifuge at 12000rpm - Spin column with collection tube for an 
additional 2 min. This step is essential to avoid residual ethanol. 
13. Discard collection tube and transfer the Purefast spin column into a fresh  
1.5 ml micro centrifuge tube. 
14. Add 100µl of the pre-warmed Elution Buffer to the centre of Purefast spin 
column membrane. Take care not to contact the membrane with the pipette 
tip. 
15. Incubate for 2 min at room temperature and Centrifuge at 13000rpm for 1 
min. Discard the spin column and store the purified DNA at -20°C. Note: 
Elution volume can be adjusted from 30µl to 100µl. 
PCR 
HELINI Ready to use Klebsiella pneumoniae Primer mix - 5µl/reaction 
PCR Product: 200bp 
Gene: hemolysin gene 
HELINI-F: TTCATCTACGTGCTGGAGGG 
HELINI-R: AGCCTGGATTGAGCGGATAA 
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RESULTS AND INTERPRETATION 
In this study 100 samples of BAL from chronic respiratory diseases 
cases were microbiologically analyzed for bacterial and fungal profile and the 
results are given below. 
TABLE 1- AGE AND SEX DISTRIBUTION IN CHRONIC 
RESPIRATORY DISESASE. 
 
Age Male % Female % 
< 20 1 2% 0 0 
21-40 2 5% 13 26% 
41-60 27 68% 24 47% 
61 and above 10 25% 14 27% 
Total 49 
 
51 
 
Mean 10 
 
12.75 
 
SD 12.02775 
 
9.844626 
 
 
The age and sex distribution of the study population is shown in the 
above table. In this study female population had a slight increase in incidence 
51% than male population which was 49 %.  The commonest age group 
affected in the study was between 41 and 60. In this group male population 
was affected 68 % more than the female population which was only 47 %. 
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FIGURE-1 AGE AND SEX DISTRIBUTION IN CHRONIC 
RESPIRATORY DISEASES. 
 
 
 
 
FIGURE- 2 GENDER DISTRIBUTION IN CHRONIC RESPIRATORY 
DISEASES. 
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TABLE 2- PERCENTAGE OF GRAM POSITIVE AND GRAM 
NEGATIVE INFECTION AMONG CLINICAL CONDITIONS 
 
 Cases G (+) G (+) % G (-) G (-) % 
COPD 27 6 38% 6 43% 
Asthma 21 3 19% 1 7% 
 Chronic Bronchitis 30 4 25% 4 29% 
Chronic Pleural Disease 6 1 6% - - 
Emphysema 9 1 6% 3 21% 
Pulmonary Fibrosis 6 1 6% - - 
Cystic Fibrosis 1 - - - - 
Total  100 16  14  
 
G (+)- Gram positive; G (-)- Gram negative 
Among the Chronic respiratory diseases the common occurrence was 
Chronic Bronchitis 30% followed by COPD 27% and Asthma amounting for 
21%. Lower respiratory tract infection was observed more among COPD  in 
which Gram negative organism was 43 % and Gram positive organism was 
38%. This was followed by Chronic bronchitis in which Gram negative 
organism was 29 % and Gram positive organism was 25 %. Asthma cases had 
infection associated more with Gram positive organisms 19% than Gram 
negative organism 7%. 
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FIGURE 3- DISTRIBUTION OF DISEASES AMONG CHRONIC 
RESPIRATORY DISEASES CASES 
 
 
 
In our study chronic bronchitis accounts to 30%, followed by COPD 
27% and Asthma 21% and chronic respiratory diseases. 
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TABLE 3- PROFILE OF THE PATHOGENS 
Type of Organisms No of Cases Percentage (%) 
Staphylococcus aureus 5 14 %  
Acinetobactor baumanii 5 14 % 
Enterococcus faecalis 2 6 % 
Streptococcus pneumoniae 3 8 % 
Pseudomonas aeuroginosa 1 3 % 
Escherichia coli 2 6 % 
Klebsiella pneumoniae 7 20 % 
Candida albicans 5 14 % 
Aspergillus flavus 2 6 % 
Aspergillus niger 2 6 % 
Aspergillus fumigatus 1 3 % 
Total 35  
 
In this study a total of 35 organisms were isolated. Out of which 25 
isolates were bacteria and 10 isolates were fungus. Among bacterias gram 
negative organisms were isolated more than gram positive organisms. 
Klebsiella pneumoniae was the commonest bacteria isolated accounting to 
20%. It was also noted that Klebsiella pneumoniae was also the commonest 
gram negative bacteria isolated. Staphylococcus aureus was the commonest 
positive bacteria isolated. Among the fungus Candida albicans was the 
commonest isolate accounting to 14 %.  
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FIGURE 4- DISTRIBUTION OF BACTERIAL AND FUNGAL 
PATHOGENS. 
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TABLE 4- DISTRIBUTION OF GRAM POSITIVE AND GRAM           
NEGATIVE BACTERIAL PATHOGENS. 
 
 
Types of Bacteria Gram (+) 
 
Gram (-) 
 
Total 
No.Cases Percentage % 
Klebsiella pneumoniae - 7 (47%) 7 28% 
Acinetobacter baumanii - 5(33%) 5 20% 
Enterococcus faecalis 2(20%) - 2 8% 
Escherichia coli - 2 (13%) 2 8% 
Streptococcus pneumoniae 3(30%) - 3 12% 
Staphylococcus aureus 5(50%) - 5 20% 
Pseudomonas aeuroginosa - 1(7%) 1 4% 
Total  10 15 25 
 
 
 
 
 
The above table shows Gram negative infections are common in chronic 
respiratory disease which is 68% of bacterial infections. Klebsiella 
pneumoniae is the commonest among Gram negative bacteria followed by 
Acinetobacter baumanii. 
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FIGURE 5- PERCENTAGE AND DISTRIBUTION OF BACTERIAL 
ISOLATES. 
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TABLE 5: PERCENTAGE AND DISTRIBUTION OF FUNGAL 
ISOLATES. 
 
 
 
Type of Fungus No of Cases Percentage (%) 
Candida albicans 5 50% 
Aspergillus flavus 2 20% 
Aspergillus niger 2 20% 
Aspergillus fumigatus 1 10% 
Total 10  
 
 
 
 
 
Out of the 100 sample 10 samples showed positive for fungal culture. 
Out of the fungal culture positive samples Candida albicans was 50% , 
Aspergillus flavus 20%, Aspergillus niger 20% and Aspergillus fumigates 
10%. 
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FIGURE 6- PERCENTAGE OF FUNGAL ISOLATES. 
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TABLE 6-PREVALENCE OF GRAM POSITIVE, GRAM NEGATIVE 
ORGANISMS AND FUNGUS. 
 
GRAM NEGATIVE BACTERIA GRAM POSITIVE BACTERIA FUNGUS  
KLEB. 
PNEUM 
ACINE. 
BAUNAMII 
ESHER. 
COLI 
PSEUD. 
AEURO 
STAPHY. 
AUREUS 
STREPT. 
PNEUMO 
ENTERO. 
FAECALI 
CANDIDA 
ALBICAN 
ASPER. 
FLAVUS 
ASPER 
NIGER 
ASPER. 
FUMI 
7 5 2 1 5 3 2 5 2 2 1 
 
 
 
Gram negative bacterias were isolated more than Gram positive bacterias. In 
fungus candida and aspergillus isolates were equal in number. 
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FIGURE 7-PREVALENCE OF GRAM POSITIVE ORGANISMS 
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FIGURE 8- PREVALENCE OF GRAM NEGATIVE ORGANISMS 
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TABLE 7- 
ANTIBIOTICS RESISTANCE PATTERN GRAM NEGATIVE & 
POSITIVE PATHEGONS 
 
Antibiotics 
 
 
 
Klebsiella 
pneumoniae 
(7) 
 
 
Acinetobater 
baumanii 
 
(5) 
 
 
Escherichia 
coli 
 
(2) 
 
 
Pseudomonas 
aeruginosa 
 
(1) 
 
Staphylococcus 
aureus 
 
(5) 
 
 
Streptococc
us 
pneumonia 
 
(3) 
 
 
Enterococcus 
faecalis 
 
(2) 
 
 
 
 
Amikacin 
 
0 1(20%) 1(50%) 
 
0 0 0 0 
 
 
Amoxicillin/ 
Clavulanic 
 
 
3(43%) 3(60%) 2(100%) 
 
0 3(60%) 1(33%) 2(100%) 
 
 
Clindamycin 
 
 
0 0 0 
 
0 0 1(33%) 0 
 
Cefoperazoine 1(14%) 2(40%) 1(50%)  0 0 1(33%) 0 
 
Cefepime 1(14%) 2(40%) 1(50%) 
 
        0           0 
 
1(33%) 
 
1(50%) 
 
 
Imipenem 
 
 
0 2(40%) 
 
0 
 
0 0 0 0 
 
 
Linezolid 
 
 
0 0 
 
0 
 
0 0 0 0 
 
 
Vancomycin 
 
 
0 0 
 
0 
 
0 0 0 0 
 
Piperacillin      
 
 
 
 
 
 
/Tazobactam 0 1(20%) 
 
0  0 0 0 0 
 
        
 
 
Antimicrobial resistance is noted more among Gram negative bacterias 
than Gram positive bacterias in lower respiratory tract infections. There is a 
high amount of resistance to Amoxicillin/Clavulanic acid for both Gram 
positive and Gram Negative bacterias. Among all bacterias Pseudomonas 
aeruginosa shows least resistance and Acinetobacter baumanii shows highest 
resistance pattern. 
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FIGURE 9- ANTIBIOTIC RESISTANCE PATTERNS 
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FIGURE 10- ANTIBIOTIC SENSITIVITY PATTERN 
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TABLE 8- AGE PREVELANCE AMONG DIFFERENT PATHOGENS 
 
 
       ISOLATES 
 
 
 
AGE 
 
 
St
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is 
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o
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pn
eu
m
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n
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e 
K
le
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ie
lla
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eu
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o
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r 
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ii 
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a 
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n
s 
A
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s 
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u
s 
A
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s 
n
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er
 
A
sp
er
gi
llu
sf
u
m
ig
at
u
s 
1-30 0 0 0 0 0 0 0 1 0 1 0 
31-60 4 1 0 5 0 4 1 3 1 0 1 
61-90 1 1 3 2 1 1 1 1 1 1 0 
Total 5 2 3 7 1 5 2 5 2 2 1 
 
 
From this table we observe that pulmonary infection are more common 
among 31-60 age group and less common among below 30 years of age. 
Bacterial infections are more common in the age group of 31-60 years with 
predominant Gram negative infections. In the age group above 60 years 
bacterial infections occurs equally with both Gram positive and Gram negative 
bacterias . 
 
 
 
 
79 
 
 
PCR RESULT 
HELINI Ready to use Klebsiella pneumoniae Primer mix - 5µl/reaction 
PCR Product: 200bp 
Gene: hemolysin gene 
HELINI-F: TTCATCTACGTGCTGGAGGG 
HELINI-R: AGCCTGGATTGAGCGGATAA 
FIGURE 11 : GEL ELECTROPHOROSIS 
 
 
1st well- Negative control. 
2nd well- Reference ladder. 
3rd well onwards sample wells- All the samples have been noted at 200 
base pairs expected of Klebsiella pneumoniae. 
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DISCUSSION 
Bacterial infections are generally considered to be the most common 
cause of lower respiratory tract infection in chronic lung disease patients. 
Proper identification of respiratory pathogen from BAL is central for the 
treatment of pulmonary infections. 
Use of invasive techniques like bronchoscopic specimens like BAL fluid 
has led to better diagnosis of the lower respiratory tract infection. 
In non-ventilated patient, semi quantitative culture of BAL fluid have 
shown to have significiant predicative value for lower respiratory tract 
infection. 
Klebsillea pneumoniae is one of the important Gram-negative bacteria in 
nosocomial infections. Antibiotic resistant isolates make therapeutic challenge 
in treatment of the patient. 
 Acinetobacter baumanni is another Gram negative bacteria in hospital 
acquired infections and particularly pose problems due to large numbers of 
Multi drug resistant strains. This is a matter of great concern. 
Candida spp and Aspergillus spp contribute to the large bulk of 
pulmonary mycoses in fungal reporting. 
Chronic respiratory diseases are public health problems due to their 
frequency of occurrence and financial impact on both developed and 
developing countries like ours. It is also a major contributor of motility and 
morbidity worldwide. Our study was conducted with the aim of determining 
the bacterial and fungal causative agents associated with chronic respiratory 
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disease and also to estimate the antimicrobial sensitivity for the bacterial 
isolates. 
Chronic respiratory disease cases were more among the age group of 
above 40 years in our study which correlates with studies like Mullerova et al 
(45%)12 and Merino- Sanchez et al (60%).13 
In lower respiratory tract infections BAL is a very useful diagnostic tool. 
This study showed a positive bacterial culture in 35 % of the cases of lung 
infection. This percentage is lower than when compared with studies like Velez 
et al (51.6%)14, Kottmann et al (55.6%)15 as they were done on 
immunocompromised patients. This study is in consistant with Vivek KU, 
Nutan Kumar study (38 %)30 as both of the studies were carried out on general 
population. 
In our study, aerobic gram negative bacterias were 42 % and aerobic gram 
positive bacterias were 28 %. The percentage of gram negative bacterias are 
lower when compared with studies like Groenewegen and Wouters (71%)16 
with suspected pneumonia in COPD and Vivek KU and Nutan Kumar (65.7%). 
On the other hand our study is in consistence with gram positive bacterias 27% 
and 34.5% respectively. 
We observed klebisellia as the commonest pathogen isolated in this study 
which was 20%. This is in correlation with studies undertaken by Lin SH et al 
(19.6%) 17and Vivek KU and Nutan Kumar (26%)30. Klebsiella being part of 
normal flora of mouth and commonly associated with pneumonia in elderly 
and hospitalized patients may been the reason of more isolation of the 
organism in our study. 
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Comparison of  bacterial pathogens isolated in chronic respiratory disease 
from different studies. 
Study Total isolates Klebsiella Acinetobacter 
S. 
aureus 
S. 
pneumoniae 
Pseudomonas 
aeroginosa 
Torres 
et al 
(1998)19 
73 - - - 43% - 
Lin SH 
et al 
(2007)17 
328 19.6% 6.9% 6.1% 2.4% 16.8% 
Bari et 
al 
(2010)20 
60 13.3% 6% - 3% 25% 
Vivek 
KU 
(2016)30 
42 26% 14.2% 11.9% 9.5% 2% 
This 
study 25 20% 14% 14% 8% 3% 
 
 
   In this study Gram negative bacterias shows more antibiotic resistance 
when compared with Gram positive bacterias. Among Gram negative bacterisa 
Acenitobacter baumanii exhibits highest resistance followed by Klebsiella 
pneumoniae and E. coli. Least resistance was show by Pseudonomas 
aeruginosa. 
In Gram positive  bacteria Staphylococcus aureus are resistant to 
Amoxicillin/clavulanic acid and exhibit sensitivity to other antibiotic. 
Streptococcus pneumonia shows 33% resistance to Amoxicillin/Clavulanic 
acid, clindamycin and cephalosporins. Enterococcus exhibits high resistance to 
Amoxicillin/clavulanic acid. All bacterial isolates were sensitive to Linezolid 
and vancomycin. 
Low number of bacterial isolates may be due to prior use of antibiotics. 
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 Comparison of fungal isolates in various studies of chronic respiratory 
diseases. 
Study No of 
isolates 
Candida 
albicans 
Aspergillus 
niger 
Aspergillus 
flavus 
Aspergillus 
fumigates 
Vivek 
KU30 
27 10 % 2 % 1 % 1 % 
Our study 10 14 % 6 % 6 % 3 % 
 
Our study correlates with Vivek where the commonest fungus associated 
with lower respiratory tract infection was candida albicans.  Followed by 
Aspergillus species. 
Conventional PCR test performed on samples of commonest isolate was 
tested for hemolysin gene for Klebsiella pneumoniae and were noted on 200 
base pairs for Klebsiella pneumoniae in the post PCR product. PCR test was 
concordant with the phenotypic test.  
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SUMMARY 
This one year prospective study was conducted among chronic 
respiratory diseases patients undergoing bronchoscopy admitted in the 
Department of Thoracic Medicine, Thanjavur Medical College and hospital. 
A total of 100 BAL samples which was processed for Bacterial and 
fungal agents from May 2015 to April 2016 at Department of Microbiology, 
Thanjavur Medical College was included in this study. 
          The BAL sample was examined macroscopically for appearance of 
visible blood and microscopically for the presence of bacteria and fungus by 
KOH mount and Grams stain. Subsequently the sample was inoculated on Mac 
conkey, Blood, Chocolate ager by semi quantitative method for bacterial 
growth. It was also inoculated on SDA for fungal growth. All bacterial growth 
were biochemically test for identification of the organism. Antimicrobial 
sensitivity was done on the bacterial isolates and the results noted. Klebsiella 
pneumoniae were isolated in 7 samples and the commonest organism. These 
samples were send for conventional PCR testing for identification of 
hemolysin gene for confirmation.  
• Out of the hundred cases 51 were female and 49 were males. 
• The incidence of chronic respiratory diseases was more among male 
cases. 
• Chronic bronchitis 30% cases were observed more in this study. 
• Lower respiratory tract infections were common among COPD cases. 
• Incidence of bacterial infection was 25 % and fungal infection was 10 %. 
• Negative for bacterial culture was 75 %. 
• Negative for Fungal culture was 90 %. 
• Negative culture for both bacteria and fungus were 65 %. 
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• The percentage of pathogens causing lower respiratory infection in 
Chronic respiratory diseases patient was 43 % gram-negative bacteria,28 
% gram positive bacteria,14 % of yeast and 15 % of Dimorphic fungi. 
• Among the gram negative bacteria, the predominant pathogen was 
Klebsiella pneumoniae 46%, Acinetobacter baumanii 33%, Escherichia 
coli 13% and Pseudomonas aeuroginosa 6%. 
• Among the gram positive bacteria, the predominant pathogen was 
Staphylococcus aureus 50%, Streptococcus pneumonia 30% and 
Enterococcus faecalis 20%. 
• Among the fungus candida was 50% and Aspergillus was 50%.  
• High antimicrobial resistance was noted in Acenitobacter baumanii and 
the least antimicrobial resistance was noted in pseudomonas aeruginosa. 
• 7 samples of Klebsiella pneumoniae isolated were send for conventional 
PCR and test positive for hemolysin gene and confirmed as Klebsiella 
pneumoniae by molecular method. 
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CONCLUSION 
It is important to diagnose chronic respiratory diseases much early before 
clinically evident stage to prevent and reduce infection related morbidity and 
mortality. 
Results from BAL fluid analysis have to be evaluated with regard to the 
underlying disease and the whole clinical picture in chronic respiratory 
diseases patients. 
It is evident that the colonizing microbial flora of the respiratory tract are 
responsible for infections in Chronic Respiratory diseases and frequent cause 
of exacerbations.  
Phenotypic tests are economical and so can be used for screening. PCR 
molecular characterization of the isolates are costlier. This may be utilized to 
identify drug resistance pattern in the isolates which can influence the choice 
of antibiotic therapy.  
Gram negative bacterial infections are on the rise with high prevalence of 
drug resistance. Prompt treatment with appropriate antibiotics with improve 
the outcome of the disease and decrease the number of episodes of 
exacerbation and severity of the disease. 
Inappropriate choice of antibiotic and inadequate treatment poses a risk of 
Multidrug resistant pathogens which are difficult to treat and needs higher 
antibiotics which are expensive and not afford to many in our setting. 
Institutional antibiograms are an important tool for detecting and 
monitoring antimicrobial resistance patterns among microbial pathogens. This 
can help in guiding the policy making decisions for the ethical use of 
antibiotics in treatment setting. 
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64 31 F Asthma No Growth  __ __ __ __ __ __ __ __ __ __ 
65 68 M COPD No Growth  __ __ __ __ __ __ __ __ __ __ 
SNO AGE SEX DIAGNOSIS ORGANISM AK 30µg 
AU 
20/10 
µg 
CY 
2 µg 
CF 
75 
µg 
CPM 
30µg 
I 
10µg 
LZ 
30µg 
VA 
30 
µg 
PT 
100/10 
µg 
PCR 
66 28 M Chronic Pleural disease No Growth  __ __ __ __ __ __ __ __ __ __ 
67 43 M Bronchiectasis No Growth  __ __ __ __ __ __ __ __ __ __ 
68 40 F Asthma No Growth __  __  __  __  __  __  __  __  __  __ 
69 67 M COPD Aspergillus 
niger __   __  __  __  __  __  __  __  __  __ 
70 53 M Emphysema No Growth __   __  __  __  __  __  __  __  __  __ 
71 60 F COPD No Growth __   __  __  __  __  __  __  __  __  __ 
72 38 F Bronchiectasis No Growth  __  __  __  __  __  __  __  __  __  __ 
73 43 M Bronchitis No Growth  __  __  __  __  __  __  __  __  __  __ 
74 60 F COPD Klebsellia pneumoniae S R No S S S No No S P 
75 45 F Pulmonary fibrosis 
Candida 
albicans  __  __  __  __  __  __  __  __  __  __ 
76 30 F Asthma No Growth __   __  __  __  __  __  __  __  __  __ 
77 58 M Bronchiectasis Klebsiella pneumoniae S R No S S S No No S P 
78 70 M COPD No Growth  __  __  __  __  __   __  __  __  __  __ 
SNO AGE SEX DIAGNOSIS ORGANISM AK 30µg 
AU 
20/10 
µg 
CY 
2 µg 
CF 
75 
µg 
CPM 
30µg 
I 
10µg 
LZ 
30µg 
VA 
30 
µg 
PT 
100/10 
µg 
PCR 
79 35 M Asthma No Growth  __  __  __  __  __  __  __  __  __  __ 
80 65 M COPD No Growth __   __  __  __  __  __  __  __  __  __ 
81 74 M COPD No Growth  __  __  __  __  __  __  __  __  __  __ 
82 66 F COPD No Growth __   __  __  __  __  __  __  __  __  __ 
83 70 M COPD Klebsiella pneumoniae S S No S S S No No S P 
84 35 M Asthma Acinetobacter baumanni S S No S S S No No S __ 
85 42 M Bronchitis No Growth  __  __  __  __  __  __  __  __  __  __ 
86 60 F COPD Klebsiella pneumoniae S S No S S S No No S P 
87 55 F Bronchiectasis No Growth __   __  __  __  __  __  __  __  __  __ 
88 70 F COPD No Growth __   __  __  __  __  __  __  __  __  __ 
89 75 M COPD No Growth __   __  __  __  __  __  __  __  __  __ 
90 37 M Asthma Candida 
albicans __   __  __  __  __  __  __  __  __  __ 
91 37 F Bronchiectasis No Growth __   __  __  __  __  __  __  __  __  __ 
SNO AGE SEX DIAGNOSIS ORGANISM AK 30µg 
AU 
20/10 
µg 
CY 
2 µg 
CF 
75 
µg 
CPM 
30µg 
I 
10µg 
LZ 
30µg 
VA 
30 
µg 
PT 
100/10 
µg 
PCR 
92 42 M Chronic Pleural disease No Growth __   __  __  __  __  __  __  __  __  __ 
93 60 F COPD No Growth __   __  __  __  __  __  __  __  __  __ 
94 36 F Bronchietasis Klebsiella pneumoniae S S No S S S No No S P 
95 42 M Bronchitis Candida 
albicans  __  __  __  __  __  __  __  __  __  __ 
96 60 M COPD Klebsiella pneumoniae S S No S S S No No S P 
97 48 F Bronchitis Acinetobacter baumanni S S No S S S No No S __ 
98 25 M Asthma Aspergillus 
niger  __  __  __  __  __  __  __  __  __  __ 
99 47 F Asthma Aspergillus fumigates __   __  __  __  __  __  __  __  __  __ 
100 24 M Asthma Candida 
albicans  __ __  __  __  __  __  __  __  __  __ 
 
AK – AMIKACIN; AU – AMOXICILLIN/CLAVULANIC ACID; CY – CLINDAMYCIN; CF – CEFOPERAZONE;  
CPM – CEFEPIME;  
I – IMEPENAM; LZ – LINEZOLIDE; VA – VANCOMYCIN; PT – PIPERACILLIN/TAZOBACTAM; 
S – SENSITIVE; R – RESISTANT; NO – NO DISC RECOMMENDED 
P – PCR POSITIVE 
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APPENDIX 1 
Potassium Hydroxide Mount 
Principle 
The KOH clears out the background scales or cell membranes that may be 
confused with fungal hyphal elements in microscopy of clinical specimens. Gentle 
heating also accelerates clearing of artifacts. 
Procedure 
1. Emulsify the specimen in a drop of 10% KOH on a microscopic slide with 
the help of a loop. 
2. Apply gentle heat by passing the slide over a Bunsen flame for 3-4 times. 
3. Cover the smear with the cover slip. 
4. Leave it for 5-10 minutes. 
5. Examine the slide under low (10X) and high power (40X) magnifications. 
6. Examine the slide for 15-20 minutes for demonstration of shining fungal 
elements. 
 
 
 
APPENDIX 2 
Gram’s Staining 
Procedure 
1. Cover the smear with methyl violet (basic dye). Allow it to stand for one 
minute. 
2. Rinse the smear gently under tap water. 
3. Cover the smear with Gram’s iodine (mordant) and allow it to stand for one 
minute. 
4. Rinse the smear again gently under tap water. 
5. Decolourise the smear with 95% alcohol. 
6. Rinse the smear again gently under tap water. 
7. Cover the smear with dilute carbol fuchsin (counter stain) for 30 seconds to 
1 minute. 
8. Rinse the smear again gently under tap waterand air dry it. 
9. Observe the smear first under low power (10X) objective and then under oil 
immersion (100X) objective. 
10. Record the observation. 
 
 
APPENDIX 3 
Acid-Fast Staining (Ziehl-Neelsen) 
Procedure 
1. Heat fix the smear by passing the slide 2-3 times gently over the flame with 
the smear side up. Allow the smear to be air dried. 
2. Put the smears on a slide rack and cover the smears with strong carbol 
fuchsin. Allow it to stain for 5 minutes. 
3. Heat the slide intermittently. 
4. Rinse the smear gently under tap water. 
5. Cover the smear with 20% sulphuric acid for at least 10 minutes for 
decolourisation. 
6. Wash the slides thoroughly with water to remove all traces of acid. 
7. Cover the smear with Loeffler’s methylene blue for 15-20 seconds. 
8. Rinse the smear again under tap water and air dry. 
9. Observe the smear first under low power (10X) objective and then under oil 
immersion (100X) objective. 
10. Record the observation. 
 
 
APPENDIX 4 
Modified Acid-Fast (Kinyoun’s) stain 
To stain Nocardia by Kinyoun Acid fast staining method. 
Procedure 
1. Prepare smear and fix with heat. 
2. Added strong carbol fuchsin over the smear. Allow it to act for 5 minutes. 
Stain need to be heated. 
3. Decolourize with 1% sulphuric acid and wash. 
4. Counter stain with methylene blue for 1 minute and wash. 
5. Dry the slide in air and examine under oil immersion  and record the 
findings. 
 
 
 
 
 
 
APPENDIX 5 
May-Grunwald Giemsa Stain 
Procedure 
1. Fix the smear with methanol for 5 to 10 minutes. 
2. Stain in diluted May-Grunwald solution for 10 minutes. 
3. Without washing transfer the slide to working Giemsa stain. 
4. Stain in Giemsa solution for 15 minutes. 
5. Wash and differentiate by keeping the water on slides for 1-2 minutes until 
desired colour balance is achieved. 
6. Air dry, mount and examine under the microscope. 
 
 
 
 
 
 
 
APPENDIX 6 
Nutrient agar 
Prepared from ready to used dehydrated powder. 
Contents 
Peptone 
Lab-Lemco powder 
Yeast extract 
Sodium chloride 
Agar 
Nutrient agar is used at a concentration of 2.8 g in 100 ml of distilled water. 
1. Sterilize by autoclaving at 121˚C for 15 minutes. 
2. Dispense aseptically the requied amount of nutrient agar. 
3. Store in cool dark place. 
 
 
 
 
 
APPENDIX 7 
Blood agar 
Contents 
Nutrient agar 500 ml 
Sterile defibrinated blood 25 ml 
1. Sterilize the medium by autoclaving at 121˚C for 15 minutes. Transfer to a 
50 ml water bath. 
2. When the agar is colled to 50˚C, add aseptically the sterile blood and mix 
gently but well. Avoid air bubble formation. 
3. Dispense aspectically in 15 ml amounts in sterile petri dishes. 
4. Store the plates at 2-8˚C in plastic bags to prevent loss of moisture. 
 
 
 
 
 
 
 
APPENDIX 8 
CHOCOLATE AGAR 
When blood agar is heated, red cells are lysed and the medium becomes brown in 
color. 
It supplies the growth factors required for the growth of fastidious organisms. 
1. Heat the medium in a 70˚C water bath until it becomes brown in colour. This 
takes about 10-15 minutes. During this time the media should be mixed 
gently several times. 
2. Allow the medium to cool to about 45˚C, remix and dispense in sterile petri 
dishes. 
3. Store the plates at 2-8˚C in plastic bags. 
 
 
 
 
 
 
 
APPENDIX 9 
MacConkey agar 
Prepared from ready to use dehydrated powder. 
Content: 
Peptone. 
Lactose. 
Bile salts. 
Sodium chloride. 
Neutral red. 
Agar. 
The medium is used at a concentration 5.2 g in 100 ml distilled water. 
1. Sterilize the media by autoclaving at 121˚C for 15 mins. 
2. When the medium has cooled to 50-55˚C, mix well and dispense aseptically 
in sterile petri dishes. 
3. Store the plates at 2-8˚C in plastic bags to prevent loss of moisture. 
 
 
 
 
APPENDIX 10 
Sabouraud Dextrose Agar 
Basal media used to isolate common fungal pathogens. 
Ingredients 
Peptone                 10 gm 
Dextrose               40 gm 
Agar                     20 gm 
Distilled water     1000 ml 
Preparation 
1. Autoclave the above ingredients at 121˚C for 15 minutes and adjust final pH 
at 5.6. 
2. Dispense in tubes and allow to cool in slanted position. 
 
 
 
 
APPENDIX 11 
Mueller-Hinton Agar 
Beef extract                    2 gms 
Acidicase Peptone          7.5 gms 
Starch                             1.5 gms 
Agar                               17 gms 
Distilled water               1000 ml 
Dissolve the ingredients in one liter of distilled water. Mix thoroughly. Heat with 
frequent agitation and boil for one minute. Adjust pH to 7.4 ± 0.2. Sterilize by 
autoclaving.  
Use 
Standard medium for antimicrobial susceptibility testing. 
 
 
 
 
